跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AS-101
首页
药物
AS-101
AS-101
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Use of tumor susceptibilty gene 101 (TSG 101) as a prognostic and diagnostic marker
申请人: UNIV TEXAS
优先权: 2007
US
2 件公开
MIL-101 (Fe)-PA as well as preparation method and application thereof
申请人: UNIV GUANGDONG PHARM
优先权: 2023
CN
DNA nano compound LGHL-101 as well as preparation method and application thereof
申请人: THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
优先权: 2025
CN
Injectable hydrogel based on MIL-101 (CuFe) peroxide nano-enzyme as well as preparation method and application of injectable hydrogel
申请人: ZHEJIANG SCI TECH UNIV TONGXIANG RESEARCH INSTITUTE CO LTD
优先权: 2023
CN
ACS-101 [dichloroacetate (DCA)] as main ingredient of health-care product with function of lowering blood sugar level
申请人: YONGJUN ZHAO
优先权: 2010
CN
Exosome miR-101-3p and miR-101-3p antagonist and application thereof
申请人: AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH
优先权: 2024
CN
Solid preparation for oral use
申请人: KYORIN SEIYAKU KK
优先权: 2003
US
Novel bifidobacterium longum as well as microbial preparation, product and application thereof
申请人: SHENZHEN JUNCHANGYI BIOTECHNOLOGY CO LTD
优先权: 2024
CN
药物
反馈